US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
43.54
-0.46 (-1.05%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
↗
September 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Via
The Motley Fool
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
September 22, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates
↗
July 29, 2026
Via
Chartmill
Topics
Earnings
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
↗
September 20, 2026
Shares of Ionis are down more than 40% so far this year.
Via
The Motley Fool
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
↗
September 19, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while...
Via
MarketBeat
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
↗
September 14, 2026
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Via
The Motley Fool
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
↗
September 09, 2026
Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.
Via
The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session.
↗
September 04, 2026
Via
Chartmill
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 04, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
↗
September 04, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive...
Via
MarketBeat
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
September 03, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to present at upcoming investor conferences
September 03, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
↗
September 03, 2026
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
Via
The Motley Fool
Breakfast News: A Conversation With Ionis CEO
↗
August 22, 2026
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.
Via
The Motley Fool
Topics
ETFs
World Trade
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
August 20, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
↗
August 16, 2026
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Via
The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
↗
August 14, 2026
A drug that didn't meet expectations in a trial is to blame.
Via
The Motley Fool
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
August 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Ionis (IONS) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.
Via
The Motley Fool
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
↗
August 03, 2026
Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.
Via
The Motley Fool
Topics
Regulatory Compliance
Ionis Pharmaceuticals Q2 Earnings Call Highlights
↗
July 29, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch...
Via
MarketBeat
Topics
Earnings
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
July 29, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
July 29, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Cathie Wood Just Bet Big on This Biotech Stock
↗
July 18, 2026
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?
Via
The Motley Fool
Topics
ETFs
Ionis to hold second quarter 2026 financial results webcast
July 15, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
